Breathe Well Live Well
|
FDA approves Spiriva Respimat for asthma in adults, adolescents
Healio “The [FDA] approval of Spiriva Respimat in asthma establishes a new class of inhaled asthma therapy and provides an efficacious, new option for patients,” William Mezzanotte, MD, MPH, said in the release. “There is extensive clinical evidence … |
View full post on asthma – Google News
Conditions: Asthma; Perennial Allergic Rhinitis,
Intervention: Biological: Mouse Allergenic Extract
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); Inner-City Asthma Consortium
Recruiting – verified August 2015
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
Condition: Healthy
Interventions: Other: 10l/min; Other: 30l/min; Other: 50l/min
Sponsor: Universidade Federal de Pernambuco
Recruiting – verified August 2015
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
|
Canada Approves Breo Ellipta for Adults With Asthma
Medscape Canadian regulators have approved the dry powder combination of fluticasone furoate and vilanterol (Breo Ellipta, GlaxoSmithKline/Theravance) for once-a-day treatment of asthma in adults with reversible obstructive airways disease, GlaxoSmithKline … |
View full post on asthma – Google News
|
GSK Gets Canadian Approval For BREO ELLIPTA For Treatment Of Asthma In Adults
Nasdaq BREO® ELLIPTA is a fixed-dose combination of the inhaled corticosteroid fluticasone furoate and the long-acting beta2-agonist vilanterol. Two strengths, 100/25 mcg and 200/25 mcg, have been approved in Canada for use in asthma. BREO is administered … GSK-Theravance's Breo Ellipta gets Canadian approval to treat asthma in adults GSK Receives Approval for BREO(R) ELLIPTA(R) for the Treatment of Adults With … |
View full post on asthma – Google News
|
GSK Gets Canadian Approval for BREO ELLIPTA for Treatment of Asthma in Adults
RTT News GlaxoSmithKline plc (GSK) and Theravance, Inc. (THRX) on Thursday announced the approval in Canada of BREO ELLIPTA for the once-daily maintenance treatment of asthma in patients aged 18 years and older with reversible obstructive airways disease. GSK Receives Approval for BREO(R) ELLIPTA(R) for the Treatment of Adults With … |
View full post on asthma – Google News
|
Self-reported adverse reactions to common foods higher in adults with asthma …
Healio Individuals with asthma more frequently report adverse reactions to foods than people without asthma, according to study results. The researchers also reported patients with asthma more frequently showed immunoglobulin-E reactivity to common foods. |
View full post on asthma – Google News
|
Asthma treatment failure more likely in older adults
Clinical Advisor HealthDay News — Asthma treatments, especially inhaled corticosteroids, are less likely to work for older patients, according to a study published in the American Journal of Respiratory and Critical Care Medicine. Researchers looked at 1,200 patients … |
View full post on asthma – Google News
Michronicleonline |
Professional Medical Center Launches New Initiative to Help Diagnose Adults …
Michronicleonline Launched earlier this year, the Professional Medical Center Asthma Project invites any resident living in Oakland or Wayne County suffering from asthma or allergy symptoms to take the ImmunoCAP test. The test can be administered at any one of … |
View full post on asthma – Google News
MedPage Today |
UPDATE 1-FDA panel backs approval of GSK asthma drug in adults
Reuters If approved, the drug would be marketed under the trade name Nucala and be the first new biologic treatment for severe asthma in more than a decade. Asthma affects more than 22 million people in the United States. Severe asthma accounts for 5 to 10 … UPDATE: Glaxo's (GSK) Severe Asthma Drug Mepolizumab Found Effective in … Asthma Drug Targeting IL-5 Wins Partial Backing From FDA Advisers FDA committee recommends approval of Nucala for adults with severe asthma |
View full post on asthma – Google News